Syndicate Bio

Syndicate Bio

Biotechnology Research

Empowering Inclusive Advancements in Global Genomics Science

About us

Syndicate Bio is a platform biotech driving genomics and precision medicine initiatives across the world’s most diverse regions. We use large scale partnerships with governments and other stakeholders to drive local precision medicine impact while creating powerful datasets that can be used for drug discovery and development.

Website
https://www.syndicate.bio
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Newark
Type
Privately Held
Specialties
genomics research, precision medicine, and biotechnology

Locations

Employees at Syndicate Bio

Updates

  • Syndicate Bio reposted this

    View profile for Abasi Ene-Obong, PhD, graphic

    Founder & CEO; builder, health tech, entrepreneur; making a positive change to the world my children and I live in, blessed to have received many awards and honors and had many successes and failures.

    Imagine, for a minute, the world’s most diverse genomic, proteomic, and omics datasets combined with deep clinical history. A dataset so rich in novel genetic variants. Now layer improved bioinformatics and AI/ML, and you get medical and scientific discoveries and significantly reduced worldwide healthcare disparities. You also get an Africa that becomes a significant player in life science R&D and drug discovery and development. At Syndicate Bio, we are taking our operational, ethical, and scientific experience previously gained as a pioneer in building one of the world's largest diverse biobanks to build what will arguably be one of the world’s most important healthcare/ life science resources. We are doing this collaboratively and inclusively, working with local governments and respecting their sovereignty over samples and data, ensuring that much of the value chain around intellectual property generation is harbored within their countries, and working with academia, local scientists, and global industry and donors. Why this approach? Because building one of the most important datasets of our lifetime requires all of us as its discoveries affect us all. Our name, “Syndicate Bio,” reflects that ethos - a shared commitment towards building a resource that improves healthcare for all of us and is done by all of us. But this time, African scientists and economies also benefit from the discoveries and intellectual property generated on the African continent. Our company and mission have received so much support for which we are grateful, and we cannot list all the support in one post. However, we want to thank our pre-seed investors, including Techstars, StoryHouse Ventures, Resilience17, Dx Angels (a digital health syndicate of Doximity alumni and other health tech leaders), and others. I always say that an organization is made up of the people in it. So I want to thank the people who are behind some of the organizations or who invested directly as well, such as Olugbenga Agboola (CEO of Flutterwave), Miles T. Bird and Josh Tatum (Founders of StoryHouse Ventures), Gbenga Oyebode ( Founder of the leading integrated Nigeria law firm ALN Nigeria | Aluko & Oyebode), Jessica Hope (CEO of Wimbart),  Mujtaba B. and Ahmed Belal (founders of Dx Angels), and Trey Bowles (MD Techstars Physical Health Fort Worth Accelerator). We have a great team of resilient and determined professionals who have and continue to support our mission made up of people like Estelle Dogbo, Wissam Hamou Ph.D, TS (ABB), Jumi Popoola, PhD, Chinyere Jacinta, Ofonime Ebong, marcus inyama Asuquo, Yusuf Ibrahim, QBRS, Aminu Yakubu, Wubrest Bekele, MD and more, and great advisors such as Peter Wilkinson (Chief Accounting Officer of Labcorp), Alon Keinan (leading computational biologist and professor at Cornell), and Sufyan Subzwari (CIO of DNAMIC | Databricks Data Solutions). Our journey is just beginning, and we have so much planned!

    • No alternative text description for this image
  • Our COO spoke to ARISE News about the alarming disparities black women with breast cancer all over the world face due to structural inadequacies and a poor understanding of the genetics of breast cancer in black women. Syndicate Bio is working to improve our understanding of cancers in a very heterogeneous African population and making world-class genomics available to people in Africa.

    View profile for Estelle Dogbo, graphic

    Cofounder | SyndicateBio (Techstars’24) BioPharma & Healthtech Operator

    Whether it’s a friend or family member, we’ve all witnessed the devastating consequences that come with a breast cancer diagnosis and what is even more alarming is that black women seem to be genetically predisposed for a diagnosis at a younger age, with the most aggressive sub-types of breast cancer. Last week, I was interviewed on the morning show of arise news TV to discuss the important topic of racial disparities in breast cancer and the role genetic testing can play in the improvement of early diagnosis, prevention and potentially survival for African Women. Breast cancer is a treatable disease which unfortunately claims over 650,000 lives each year worldwide, with 70% of casualties in Africa, imagine the impact on our communities where young women are often the caregivers of their families. This past Pink October was an opportunity to highlight our mission at Syndicate Bio, where we acknowledge the impact of genetic variations on disease outcomes, and work tirelessly to improve the availalibity of genetic testing locally, for Nigerians and Africans. Here is a short introduction of the points discussed and you can watch the full interview where we talk about the role of genomics and precision medicine by clicking on the link below: https://lnkd.in/d5-nGNZD Kudos to the Syndicate Bio team for being so committed to our goal of democratizing Precision Oncology regardless of the challenges, right next to our African patients 🌍 Abasi Ene-Obong, PhD Wissam Hamou Ph.D, TS (ABB) Yusuf Ibrahim, QBRS Chinyere Jacinta Ofonime Ebong Jumi Popoola, PhD #awarenessneverstops #genomics #PrecisionMedicine #PrecisionOncology

  • Syndicate Bio reposted this

    View profile for Abasi Ene-Obong, PhD, graphic

    Founder & CEO; builder, health tech, entrepreneur; making a positive change to the world my children and I live in, blessed to have received many awards and honors and had many successes and failures.

    I am incredibly excited to share that Syndicate Bio is expanding to Botswana and has officially been licensed by Special Economic Zones Authority of Botswana to become one of the Zone’s first companies. Our expansion to Botswana and work in SEZA will help us deliver innovative genomics and proteomics sequencing technology to the country, turning Botswana into a regional lifescience hub, capable of unlocking value in the healthcare and life science sectors for the entire continent. In addition to being a leader in Africa’s healthcare and life science sectors, Botswana’s stable economy, world-class universities and robust infrastructure position the country as the ideal partner to support our mission in Africa. We would like to thank H.E President Mokgweetsi Masisi who graced the occasion, Government of Botswana, SEZA Botswana, and our partners for making this collaboration possible and look forward to building a long-lasting impact on Africa’s genomic scene together. More to come soon!

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Syndicate Bio, graphic

    1,220 followers

    We just returned from last week’s ARCON NIGERIA 2024 Conference, where our team interacted with oncologists from across Nigeria, to discuss the most pressing needs in cancer care, including the role of genomics in cancer research and clinical management. During the event, we also launched a nationwide survey on the state of genomics adoption among oncologists in Nigeria. This survey launched in partnership with National Institute for Cancer Research and Treatment provides insights into the educational plans we will be deploying as we launch our suite of comprehensive Genomics Profiling products. We invite you to participate in this exciting open survey by clicking this link: https://lnkd.in/dcuzjSgR #Genomics #Nigeria #PrecisionMedicine #Cancer #CancerCare

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • Join us at the 2024 Association of Radiation and Clinical Oncologists in Nigeria (ARCON) Conference on September 11th, 12th, and 13th! We're excited to meet with you and here is what you can expect: - Engaging educational presentation on "Comprehensive Genomics Profiling in Nigeria" focusing on enhancing cancer outcomes through mutational drivers, targeted therapies, and clinical trials. - Explore our exhibition booth showcasing cutting-edge cancer genetic testing solutions for solid tumors and blood cancers, as well as the latest advancements in genetic testing transforming cancer care in Nigeria and beyond. Don't miss the opportunity to witness how we're advancing cancer care and personalized medicine in Nigeria! To learn more and stay updated on our genomics profiling tests, visit www.syndicate.bio and follow us on Instagram at https://lnkd.in/dt7XrFXh. #ARCON2024 #CancerCare #Genomics #PrecisionMedicine #Oncology

    • No alternative text description for this image
  • Syndicate Bio reposted this

    We’re excited to join the Techstars community, and look forward to leveraging these new connections and opportunities to drive innovations that improve health outcomes across Africa and globally! #Techstars #HealthTech #Innovation #Healthcare #PrecisionMedicine

    View profile for Trey Bowles, graphic

    Techstars Anywhere and Techstars Physical Health Fort Worth... Looking for the most innovative pre-seed and seed technology companies on the planet

    We are very happy to Announce our 2024 Techstars Physical Health Fort Worth Accelerator class. This year, rather than just 10 companies we are going to be working with 11 companies out of our program here in Fort Worth, Texas. This promises to be another amazing class and we cannot wait for you all to meet each of these companies and their founders. You can read more about each company here: https://bit.ly/tsfw2024 And you have the opportunity to meet each of them at our 2024 Kick Off Party located at Create FW on Wednesday, September 11 at 6pm. RSVP here for Free to join us at the party: https://lnkd.in/gBsW63Jh You can follow the companies on Linkedin as well: #Athlete ElectroKare FluteSpace Gale HSA Gisens Biotech Nerveli Peeq Industries Proton Health Revella Health ReviMo Syndicate Bio

    Techstars Physical Health Fort Worth Announces is Fall 2024 Class

    Techstars Physical Health Fort Worth Announces is Fall 2024 Class

    techstars.com

  • Syndicate Bio reposted this

    View profile for Abasi Ene-Obong, PhD, graphic

    Founder & CEO; builder, health tech, entrepreneur; making a positive change to the world my children and I live in, blessed to have received many awards and honors and had many successes and failures.

    Since we announced our company, Syndicate Bio, last year, we have been grateful for the support we have received from investors (angels and VC investors), technology partners, and multiple governments. Today, we are also grateful to be joining the Techstars community and excited to be joining the precision medicine-focused life science ecosystem of the larger Texas area that includes the MD Anderson Cancer Center, UT Southwestern Medical Center (the PCSK9 inhibitor drugs grew out of research here), The University of North Texas Health Science Center at Fort Worth (a Techstars Physical Health Fort Worth Accelerator), and many others. The Texas life science ecosystem has been at the forefront of improving precision medicine and drug discovery for all patients and contributing to the development of novel therapies from ethical and inclusive genomics research in some of the highly diverse regions of Texas. We look forward to collaborations that can improve the lives of patients in Africa and globally powered by genomics work in diverse populations. #texas #precisionmedicine #diversity #drugdiscovery #genomics #techstars

  • We’re excited to join the Techstars community, and look forward to leveraging these new connections and opportunities to drive innovations that improve health outcomes across Africa and globally! #Techstars #HealthTech #Innovation #Healthcare #PrecisionMedicine

    View profile for Trey Bowles, graphic

    Techstars Anywhere and Techstars Physical Health Fort Worth... Looking for the most innovative pre-seed and seed technology companies on the planet

    We are very happy to Announce our 2024 Techstars Physical Health Fort Worth Accelerator class. This year, rather than just 10 companies we are going to be working with 11 companies out of our program here in Fort Worth, Texas. This promises to be another amazing class and we cannot wait for you all to meet each of these companies and their founders. You can read more about each company here: https://bit.ly/tsfw2024 And you have the opportunity to meet each of them at our 2024 Kick Off Party located at Create FW on Wednesday, September 11 at 6pm. RSVP here for Free to join us at the party: https://lnkd.in/gBsW63Jh You can follow the companies on Linkedin as well: #Athlete ElectroKare FluteSpace Gale HSA Gisens Biotech Nerveli Peeq Industries Proton Health Revella Health ReviMo Syndicate Bio

    Techstars Physical Health Fort Worth Announces is Fall 2024 Class

    Techstars Physical Health Fort Worth Announces is Fall 2024 Class

    techstars.com

  • Throwback to when we hosted the National Institute for Cancer Research and Treatment (NICRAT) leadership, led by Professor Usman Aliyu and Dr. Waziri, at our cancer genomics laboratory in Lagos. This visit to view our genomics profiling capabilities marked a crucial step in our partnership as we prepare for the recruitment phase of the Cancer Genome Nigeria (CGN) study— aimed at uncovering the genetic drivers of Nigeria’s most prevalent cancers. In addition to CGN, we will be unveiling our suite of comprehensive genomics profiling tests for clinical oncology in a few weeks. These initiatives signify an exciting period for us, promising improved early detection and personalized treatment strategies for Nigerian patients. For the latest on our genomics profiling test offerings, follow us on Instagram: https://lnkd.in/dt7XrFXh To learn about our commitment to advancing precision medicine and improving cancer care across Africa, visit us at www.syndicate.bio. #healthcare #cancer #biotechnology #precisionmedicine #research #Africa #Nigeria 

    • No alternative text description for this image
    • No alternative text description for this image
  • We are excited to announce our collaboration with SOPHiA GENETICS to introduce the MSK-ACCESS® assay, a groundbreaking liquid biopsy test powered by SOPHiA DDM™, in Nigeria and across Africa. Developed in partnership with SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and AstraZeneca, this innovative technology represents a major breakthrough in cancer diagnostics and treatment accessibility for underserved populations in Africa. Syndicate Bio is honored to lead the charge as a pioneer biotechnology company driving the integration of liquid biopsy technology into cancer diagnostics across the continent. The MSK-ACCESS® test is a specialized approach to studying cancer-related genes and tracking the disease without invasive procedures. It looks closely at crucial genes associated with cancer, using a method called DNA sequencing. This test can find changes in DNA present in fluids like blood, without needing to take tissue samples. By using this specialized liquid biopsy test, doctors can improve how they care for cancer patients, especially in places where traditional biopsies are difficult to implement. This partnership signifies a crucial step forward in addressing the disparities in cancer care faced by underserved populations in Africa. By making advanced genomic profiling accessible through liquid biopsy testing, we aim to revolutionize cancer diagnostics and treatment strategies, ultimately improving patient outcomes and advancing the fight against cancer on the continent. The collaboration between Syndicate Bio and SOPHiA GENETICS represents the first milestone in the introduction of our portfolio of innovative oncology testing solutions. In addition, we will offer comprehensive genomic profiling for cancers such as solid tumor testing, blood cancer testing, BRCA 1 and 2 testing, and familial cancer risk testing, among others. These offerings will strengthen our commitment to advancing precision medicine and improving cancer diagnosis and treatment options for patients across the continent. Stay tuned for more updates as we continue to drive impactful change in the field of oncology and precision medicine, empowering patients and healthcare providers alike. Read more about the partnership and our newly acquired liquid biopsy technology here: https://lnkd.in/d_bQP6kb

    SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa

    SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa

    prnewswire.com

Similar pages

Browse jobs